APGE

Apogee Therapeutics' stock has shown strong performance, surging approximately 169% over the past year and increasing by 10% since the beginning of the current year. Key events include public offerings, positive Phase 2 Part A 52-week data for Zumilokibart (APG777) in moderate-to-severe atopic dermatitis, a consensus rating of "Moderate Buy" from analysts, and insider selling.